Close
We build the publications from HKU and external sources automatically. If you do not see your publications here, please note:
  • We receive data from HKU's Research Output System (ROS), after you or your people enter data there. If you have entered, or are going to enter data into ROS, we do not want to enter them manually into the Hub, as it will create duplicates. When entering data into ROS, please remember to include the DOI or ISBN. It will help us match on outside sources, and dedup.
  • If you are NOT going to enter publication data into ROS, or if you have publications from before your time at HKU, please put them into an EndNote file and send to us, hub@lib.hku.hk. It will allow us to enter in batch. HKU has a site license for EndNote. You may google for "endnote@hk". HKU Libraries can instruct on Endnote, either in class or one on one, http://lib.hku.hk/general/help.html
  • You may log into your ResearcherPage with your HKU Portal, and use the "Manage Publications" entry on the green left side menu, to unlink publications from your ResearcherPage, or, select a few to appear in a new box, "Selected Publications".
  • Confused? Please write to hub@lib.hku.hk.
HKU ResearcherPage: Tse, EWC
 
rp00471.jpg picture
Dr Tse, Eric Wai Choi
謝偉財
Title
  • Clinical Associate Professor
Dept:
Faculty:
Contact Information
rp00471.jpg picture
Office:
 Biography

Dr. Eric WC Tse

Clinical Associate Professor

BSc(BiomedSc)(HK), MBBS(HK), PhD(Cantab), FRCP, FRCP(Edin), FRCP(Glasg), FRCPath, FHKCP, FHKAM(Medicine)

 

Dr. Tse graduated MBBS with the John Anderson Gold Medal from the University of Hong Kong. He also obtained a PhD at the University of Cambridge, and was awarded the Max Perutz Research Prize by the MRC Laboratory of Molecular Biology, Cambridge. Upon completion of clinical haematology training at Queen Mary Hospital, Dr. Tse has been appointed honorary consultant physician in the Department of Medicine.

 

In addition to clinical research on the treatment of haematological malignancies, in particular T-cell and NK-cell lymphoid neoplasms, his basic and translational research have focused on the development of novel therapeutic approach in cancer treatment through identifying potential targets and understanding the fundamental biology of cancer. Dr. Tse has pioneered the development of intracellular antibodies in the therapy of cancer during his early stage of career. He is currently examining the role of peptidyl-prolyl-isomerase PIN1 and its interplay with CKS proteins in cell cycle regulation, apoptosis and DNA damage response in cancer and neurodevelopment. Furthermore, through the use of therapeutic agents to up-regulate aquaglyceroporin 9 expression, he is also investigating the possibility of extending the application of arsenic trioxide beyond the treatment of acute promyelocytic leukaemia.

 

Selected Publications

1.         Pang R, Yuen J, Yuen MF, Lai CL, Lee TK, Man K, Poon RT, Fan ST, Wong CM, Ng IO, Kwong YL and Tse E. PIN1 over-expression and β-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 23(23): 4182-6, 2004. (Impact Factor: 7.35)

2.         Pang R, Lee TK, Man K, Poon RT, Fan ST, Kwong YL and Tse E. PIN1 expression contributes to hepatic carcinogenesis. J. Pathol. 210(1):19-25, 2006. (Impact Factor: 7.58)

3.         Pang R, Lee TK, Poon RT, Fan ST, Wong KB, Kwong YL and Tse E. Pin1 interacts with a specific serine-proline motif of hepatitis B virus x-protein to enhance hepatocarcinogenesis. Gastroenterology. 32(3):1088-103, 2007. (Impact Factor: 12.82)

4.         Leung J, Pang A, Yuen WH, Kwong YL and Tse E. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukaemia cells. Blood. 109(2):740-46, 2007. (Impact Factor: 9.06)

5.         Tse E, Gill H, Loong F, Kim SJ, Ng SB, Tang T, Ko YH, Chng WJ, Lim ST, Kim WS and Kwong YL. Type II enteropathy associated T-cell lymphoma:  a multi-center analysis from the Asia Lymphoma Study Group. Am J Hematol. 87(7):663-8, 2012. (Impact Factor: 4.13)

6.         Frontini M, Kukalev A, Leo E, Ng YM, Cervantes M, Cheng CW, Holic R, Dormann D, Tse E, Pommier Y, Yu V. The CDK subunit CKS2 counteracts CKS1 to control CyclinA/CDK2 activity in maintaining replicative fidelity and neurodevelopment. Dev Cell. 23(2):356-70, 2012. (Impact Factor: 12.86)

7.         Cheng CW, Chow AK, Pang R, Fok EW, Kwong YL and Tse E. PIN1 inhibits apoptosis in hepatocellular carcinoma through modulation of anti-apoptotic function of survivin. Am J Pathol. 182(3):765-75, 2013. (Impact Factor: 4.52)

8.         Tse E and Kwong YL. How I Treat NK/T-cell Lymphoma. Blood. 121(25):4997-5005, 2013. (Impact Factor: 9.06)

9.         Yeoh AE, Tan D, Li CK, Hori H, Tse E and Pui CH. Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol. 14(12):e508-23, 2013. (Impact Factor: 25.11)

10.       Tse E, Chan TS, Koh LP, Chng, WJ, Kim WS, Tang T, Lim ST, Lie AK and Kwong YL. Allogeneic haematopoietic stem cell transplantation for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group. Bone Marrow Transplant. [in press] (Impact Factor: 3.54)

 

Research Funding

1.         GRF Award 2005-06. Research Grant Council, HK.

2.         GRF Award 2007-08. Research Grant Council, HK.

3.         Hong Kong Blood Cancer Foundation, 2010.

4.         GRF Award 2013-14. Research Grant Council, HK.

5.         Research grant for translational research, Novartis Pharmaceuticals, 2013.

 

Key Offices

  1. Founding Chairman, Hong Kong Society for Thrombosis and Haemostasis
  2. Scientific Officer, The Hong Kong Society of Haematology
  3. Council Member, Union for China Lymphoma Investigators, Chinese Society of Clinical Oncology, People’s Republic of China
 
 Honours, Awards & Prizes
Loading... 180 0 20 0 false
 Professional Societies
Loading... 150 0 20 0 false

 ! 

Close

Please give us some feedback!